The Impact of Hemodialysis and Liver Cirrhosis on the Plasma Concentrations of Tyrosine Kinase Inhibitors in a Patient with Chronic Myeloid Leukemia
-
- Taniguchi Yasuhiro
- Departments of Hematology and Rheumatology, Faculty of Medicine, Kindai University Hospital, Japan
-
- Takahashi Naoto
- Departments of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Japan
-
- Miura Masatomo
- Department of Pharmacy, Akita University Hospital, Japan
-
- Hirase Chikara
- Departments of Hematology and Rheumatology, Faculty of Medicine, Kindai University Hospital, Japan
-
- Sueda Sanae
- Department of Hematology, PL General Hospital, Japan
-
- Espinoza Jorge Luis
- Faculty of Health Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Japan Faculty of Medicine, UNIDES University, Nicaragua
-
- Rai Shinya
- Departments of Hematology and Rheumatology, Faculty of Medicine, Kindai University Hospital, Japan
-
- Nakayama Shoko
- Departments of Hematology and Rheumatology, Faculty of Medicine, Kindai University Hospital, Japan
-
- Serizawa Kentaro
- Departments of Hematology and Rheumatology, Faculty of Medicine, Kindai University Hospital, Japan
-
- Kumode Takahiro
- Departments of Hematology and Rheumatology, Faculty of Medicine, Kindai University Hospital, Japan
-
- Watatani Yosaku
- Departments of Hematology and Rheumatology, Faculty of Medicine, Kindai University Hospital, Japan
-
- Morita Yasuyoshi
- Departments of Hematology and Rheumatology, Faculty of Medicine, Kindai University Hospital, Japan
-
- Tanaka Hirokazu
- Departments of Hematology and Rheumatology, Faculty of Medicine, Kindai University Hospital, Japan
-
- Matsumura Itaru
- Departments of Hematology and Rheumatology, Faculty of Medicine, Kindai University Hospital, Japan
Search this article
Abstract
<p>We recently treated a chronic myeloid leukemia (CML) patient with liver and renal dysfunction, who was undergoing hemodialysis (HD). He was treated with 50 mg dasatinib (DAS) once daily just before HD. The maximum plasma concentration of DAS was 227 ng/mL on a non-HD day and 46.9 ng/mL on a HD day. He was subsequently treated with 200 mg bosutinib (BOS) once daily. The plasma concentration of BOS changed from 74.5 ng/mL before HD to 58.8 ng/mL after HD. Our results indicate that close monitoring of the plasma tyrosine kinase inhibitor concentrations should be considered in CML patients with organ impairment. </p>
Journal
-
- Internal Medicine
-
Internal Medicine 59 (21), 2745-2749, 2020-11-01
The Japanese Society of Internal Medicine